Molecular characterization of carbapenem and ceftazidime-avibactam-resistant Enterobacterales and horizontal spread of bla NDM-5 gene at a Lebanese medical center

Front Cell Infect Microbiol. 2024 Jun 19:14:1407246. doi: 10.3389/fcimb.2024.1407246. eCollection 2024.

Abstract

Introduction: In the battle against multidrug-resistant bacterial infections, ceftazidime- avibactam (CZA) stands as a pivotal defense, particularly against carbapenemresistant (CR) Gram-negative pathogens. However, the rise in resistance against this drug poses a significant threat to its effectiveness, highlighting the critical need for in-depth studies about its resistance mechanisms.

Methods: This research focuses on the genomic characterization of CR- and CZA-resistant Escherichia coli (n=26) and Klebsiella pneumoniae (n=34) strains, harboring the blaNDM and/or blaOXA-48-like genes, at a major Lebanese tertiary care medical center, using whole genome sequencing (WGS).

Results: Our findings revealed a notable prevalence of blaNDM in all K. pneumoniae strains isolates, with 27 of these also harboring blaOXA-48. On the other hand, E. coli strains predominantly carried the blaNDM-5 gene. Whole genome sequencing (WGS) identified a predominance of ST383 among K. pneumoniae strains, which possessed a multi-replicon IncFIB-IncHI1B plasmid harboring the blaNDM-5. Additionally, various Inc group plasmids in K. pneumoniae across multiple sequence types were found to carry the blaNDM. Similarly, diverse STs of E. coli were observed to carry blaNDM-5 on different plasmids.

Discussion: The study underscores NDM carbapenemases as a paramount resistance mechanism in Lebanon,jeopardizing critical last-resort treatments. It also illuminates the role of varied sequence types and mobile genetic elements in the spread of NDM resistance,stressing the urgent need for strategies to mitigate this threat, especially in nosocomial infections.

Keywords: Escherichia coli; Klebsiella pneumoniae; ST383; blaNDM-5; carbapenem resistance.

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Azabicyclo Compounds* / pharmacology
  • Bacterial Proteins / genetics
  • Bacterial Proteins / metabolism
  • Carbapenem-Resistant Enterobacteriaceae / drug effects
  • Carbapenem-Resistant Enterobacteriaceae / genetics
  • Carbapenem-Resistant Enterobacteriaceae / isolation & purification
  • Carbapenems* / pharmacology
  • Ceftazidime* / pharmacology
  • Drug Combinations*
  • Drug Resistance, Multiple, Bacterial* / genetics
  • Escherichia coli* / drug effects
  • Escherichia coli* / genetics
  • Gene Transfer, Horizontal
  • Genome, Bacterial
  • Humans
  • Klebsiella pneumoniae* / drug effects
  • Klebsiella pneumoniae* / genetics
  • Lebanon
  • Microbial Sensitivity Tests
  • Plasmids / genetics
  • Tertiary Care Centers
  • Whole Genome Sequencing*
  • beta-Lactamases* / genetics
  • beta-Lactamases* / metabolism

Substances

  • Ceftazidime
  • Azabicyclo Compounds
  • beta-Lactamases
  • avibactam, ceftazidime drug combination
  • Anti-Bacterial Agents
  • Carbapenems
  • Drug Combinations
  • beta lactamase NDM-5, E coli
  • Bacterial Proteins

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The study was supported by research project grants NU20J-05–00033 provided by the Czech Health Research Council and the project National Institute of Virology and Bacteriology (Program EXCELES, ID project no. LX22NPO5103) funded by the European Union–Next Generation EU.